만성 정신분열증 환자의 지속적인 항Parkinson 약물 사용 필요성에 관한 연구

A Study of the Rational for Continuous Use of Antiparkinsonian Medication in Chronic Schizophrenics

The present study was intended to clarify the need for continuous use of antiparkinsonian medication in chronic schizophrenic patients receiving long-term neuroleptic therapy. In order to achieve this goal, a double-blind five-week study of antiparkinsonian medication withdrawl was carried out to assess the clinical responses combined with extrapyramidal symptoms in 67 chronic schizophrenics who had taken continuous antiparkinsonian medication over six weeks prior to this study. The results were as follows： 1. Nineteen (43.2%) of the forty-four patients given only placebo didn’t show any change in extrapyramidal symptoms. Thus antiparkinsonian medication is not necessary for these patients. 2. Only four (17. A%) of the twenty-three patients who had been put on trihexyphenidyl (Artane？？) developed mild worsening of extrapyramidal symptoms, whereas, twenty-five (56.896) of the fortyfour patients given only placebo developed moderate to severe worsening of extrapyramidal symptoms. Additionally, psychotic flare-ups including severe anxiety, depression or delusion were also seen in this group. Thus it is assumed that a sizable proportion of chronic schizophrenics receiving sustained antiparkinsonian medication should be kept on it for clinical stability. 3. In the worsened group with placebo, symptom flareup was seen in three weeks. Our data indicate that it needs at least threeweek duration to decide whether the extrapyramidal symptoms would get worse or not after withdrawl of antiparkinsonian medication.